I hear what you're saying Mer.
I think that the whole investing community has lost sight of the plusses:
1/ The drug does something, they don't know exactly what, yet. There have been 'observed' improvements by physicians.
2/ The company has a 'raft' of other products under review.
Especially PBT434 (parkinsons), and PBT513 (glioblastome) from which a really good friend of mine recently died.
3/ The price is down to 'almost cash-value'.
For the sake of everyone I hope for a turn-around in attitude in the near future.
Regards K
... so sorry, page-19
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $23.94M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $508 | 124.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 103 | 97947018 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179262 | 15 |
View Market Depth
| Last trade - 11.42am 25/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |